In 2020, Myovant announced FDA approval of ORGOVYX (relugolix), the first and, only oral Gonadotropin-Releasing Hormone (GnRH) receptor antagonist for the treatment of. We have been hearing some strong acquisition rumors concerning AcelRx, much like we heard about Obagi last year. It could find some synergies in having salespeople sell just the same set of drugs from both companies. Additional disclosure: Disclaimer: This article is intended for informational and entertainment use only, and should not be construed as professional investment advice. Merged ALZA Corporation to Johnson & Johnson (JNJ): Mr. Rosen served as the President of ALZA Corporation. Medarex bought out GenPharm for $65M. Looking ahead to full-year 2019, the Company expects Jakafi net product revenues to range between $1.65 billion and $1.68 billion, reflecting 20% to 22% growth over the prior year. We expect approval for ValRox in Europe and the U.S. in the next few months. Antares Pharma. Scott has had the most success in trading/investing in smaller cap growth companies. There weren't that many biotech acquisitions in 2021, at least, not compared to other previous years. PwC. "Human natural killer cell" [Micrograph]. Aesther Healthcare Acquisition Corp and Ocean Biomedical, Inc. announced that AEHA has filed with the U.S. Securities and Exchange Commission a definitive proxy statement in connection with its proposed business combination with Ocean and with respect to the special meeting of Aesthers stockholders scheduled to be held on February 3, 2023. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. 2023, Nasdaq, Inc. All Rights Reserved. Therefore, I am picking 5 best Mid-cap biotech acquisition targets in this post with deal value less than $10B each. The acquisition will give Merck access to Accelereons promising pipeline candidate sotatercept which is being evaluated for the treatment of pulmonary arterial hypertension (PAH), a progressive and life-threatening blood vessel disorder. But Brian, is there a biotech buyout that you would really like to see? INCY has gained 43% year-to-date and trades around $91. Like the Medicines Co., Amarin also has a heart drug by the name Vascepa in its kitty. Healthcare. No. Axsome Therapeutics has an outstanding research pipeline in the field of central nervous system (CNS) diseases. Rumors again surfaced in 2016 that Roche would acquire BioMarin in a deal that could be in the range of $130 to $150 per share. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. The first few months lived up to expectations: All of the top 10 M&A deals of January-June 2018 exceeded $1.5 billion, paced by the completion of Bayer's $63 billion buyout of Monsanto . M&A deal flow dwindled in 2021, reflecting stricter antitrust laws. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Speights: Yeah. 2, I agree with you that the CRISPR gene-editing companies are probably near the top of the list of potential acquisition targets over the next few years. I own Vertex so I certainly don't want Vertex overpaying for CRISPR Therapeutics. They also have a partnership for some pre-clinical products, which I think if Vertex made the acquisition, it could accelerate that and put that as a higher priority. Learn More. ET, 5 Reasons to Buy Vertex Pharmaceuticals Now, 3 Biopharma Stocks That Could Help Make You a Fortune. Antares Pharma ( ATRS ) We first began to hear acquisition rumors in Antares in late 2011. BioPharma Dive is tracking these deals below. 3 Top Stocks to Buy Now and Hold Forever, Warren Buffett Is Raking in $4.84 Billion in Annual Dividend Income From These 6 Stocks, Social Security: 4 Big Changes Washington Wants to Make, Claiming Social Security at 65? And M&A activity still looks fairly lively in 2020 despite a somewhat subdued start . Avulux is pleased to announce that Axon Optics is now part of the Avulux family. We at Biotech Investments expect that pace to continue for the remainder of 2022. Mergers and acquisition (M&A) activity in India is heating up. Antares Pharma (ATRS). Analysts, on average, predict over 75% upside for Crispr shares. Meanwhile, earlier this month, U.K.-based Elliott Advisors, one of the largest stakeholders in Alexion, urged the company to take a proactive approach and put itself up for sale to maximize the chance of an optimal outcome. The company has already seven products on the market. CRISPR Therapeutics CRSP is one of the leading gene-editing companies. The company has three marketed products and boasts of a vibrant pipeline, with a host of investigational therapeutics. Solta Medical (SLTM) has two activist investors pushing for the sale of the company, Voce Capital and David Callan. And there are often rumors of other deals that never materialize. Biotech/FDA. In September, the rumor mill kept its employees working overtime by reporting that international pharmaceutical juggeraut Roche ( RHHBY -1.10%) was trying to arrange $15 billion in financing to. But the way I see it, there's plenty of biotechs in the sea to reinvest those profits. Price as of January 17, 2023, 4:00 p.m. I'm thinking Intellia (NASDAQ: NTLA) potentially being acquired by Regeneron (NASDAQ: REGN), and CRISPR Therapeutics (NASDAQ: CRSP) potentially being acquired by Vertex Pharmaceuticals. Are some major acquisitions on the way in the biopharmaceutical industry this year? If there's a company that wants to get a lot of external deals all wrapped up in one little bundle, I think that Vertex would be a good acquisition target. In the 3rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with them. Ionis (NASDAQ:IONS) is commercial-stage biopharma developing RNA-targeted therapy using antisense technology that can control gene expression in a cell using antisense oligonucleotides (ASO). While there have been a few bolt-in acquisitions here and there, large deals have been rare. Given that the FDA is yet to approve a NASH drug, it is worth taking a risk with this one-trick pony. Price as of January 17, 2023, 4:00 p.m. Sold Somatogen to Baxter International (BAX): Dr. Hoffman was the scientific founder of Somatogen Inc. Baxter bought out Somatogen for $189M. ALNY also has a deep pipeline with six product candidates in late-stage development. Additionally, Pfizer has registered a website, Otrexyo.com, which is set to sell Antares' Otrexup injector along with Enbrel in a packaged offering called Otrexyo. RTTNews->. In the wake of generic drugs eating into the sales of off-patent branded drugs, growing pressure from regulators to reduce the prices of drugs, drying pipelines, and ever-increasing R&D costs, there has been an increasing consolidation within the drug industry. Seagen has quite a few oncology drugs that would work well with the Bristol-Myers drugs. Analysts, on average, see scope for about 90% upside for Mirati stock. Disclosure: I am long ATRS, SLTM, ACRX. It is running mid-stage clinical trials of the drug, in combination with bezafibrate, in PBC, late-stage studies in non-alcoholic steatohepatitis (NASH) and a mid-stage study in biliary atresia. Youre reading a free article with opinions that may differ from The Motley Fools Premium Investing Services. With focus on discovery, development and commercialization of a strong product portfolio, collaborating with industry-leading partners such as Novartis and Sanofi Genzyme, and an outstanding therapeutics pipeline, Alnylam is one of those biotech gems big pharma companies have on their radar. Calibre Scientific is pleased to announce the acquisition of Glass Chemicals, a Spanish distributor of scientific consumables, equipment and services for the life sciences, diagnostics, and industrial sectors. In this Motley Fool Live video recorded on Jan. 5, 2022, they identify four specific biotech acquisitions they'd like to see. Now, it is three years since the PARP inhibitor has been approved. ATRS. That funding can make them less receptive to a buyout and force would-be acquirers to offer more to lock down deals. Pharma giant Pfizer recently announced that it will acquire Arena. I think that would potentially drive sales of Opdivo. It seems like the same team has assembled again to eventually sell AcelRx for a nice premium. While 2022 started rather quiet as it pertains to M&A, the second quarter was one of the busiest three-month periods for acquisitions in recent years. Scott has long positions in 3 companies mentioned in this article. In addition, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that could provide new assets for big pharmaceutical companies. Please. Powered by Madgex Job Board Software. Are you interested in learning more about small- and mid-cap biotech stocks with exceptional growth potential and some of the hottest takeover targets of the industry? 10. The speculation gained further ground when Denmark-based Novo Nordisk (NYSE:NVO) announced a deal to buy Dicerna, also a RNAi therapeutic company. Create your Watchlist to save your favorite quotes on Nasdaq.com. Today, you can download 7 Best Stocks for the Next 30 Days. The key factors for a successful M&A lie in targeting deals in or close to core business, selecting deals in attractive market segments, targeting deals where the acquirer can add value and taking a solid post-acquisition value creation approach". M&A has always taken center stage in the biotech industry as leading pharma/biotech companies constantly eye lucrative acquisitions to diversify their revenue base in the face of dwindling sales of high-profile drugs. 3. 1125 N. Charles St, Baltimore, MD 21201. Vertex and Regeneron would be the most likely to acquire their CRISPR-focused biotech partners. Is this happening to you frequently? Gene-editing company Crispr (NASDAQ:CRSP) has long been considered as a potential M&A target owing to its promising technology platform and its longstanding partnership with Vertex Pharma (NASDAQ:VRTX). 2. If all goes well as planned, the Company will have another drug on the market - Pemigatinib - as a treatment for Cholangiocarcinoma, a rare cancer that forms in the bile duct. 06-01-2023. Let's take a look at some of the biotech companies that have been in the acquisition crosshairs for quite some time. Ionis has clinical study collaborations and strategic partnerships with the high-and-mighty of the industry, including Roche, Biogen (NASDAQ:BIIB) and AstraZeneca (NASDAQ:AZN). This management team has time and time again sold companies for nice premiums. Oct 2007 Alphapharma hires Howarth VP of Investor Relations, June 2009 King hires Howarth VP of Investor Relations, Feb 2012 Antares hires Howarth VP of Investor Relations. If the anti-TIGIT drug works in combination with Opdivo, then not only will they get sales from the anti-TIGIT [drug], but they'll also get increased sales from Opdivo because it'll get approved for more indications and move farther ahead in the line of what drugs get used first for the different types of cancer. 5 min read Mergers & acquisitions (M&A) are back in focus in the biotech sector after a tepid run in the last couple of years. Any you had ideas about? Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ,TSX: NVCN)announced today that the Company has entered into a binding agreement (the Arrangement Agreement) with Shockwave Medical, Inc. (Shockwave), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the Common Shares) of the Company (the Transaction). Politics. Want the latest recommendations from Zacks Investment Research? But Alnylam's study isn't the only major readout expected this year for a genetic heart condition that's become a top target for many drugmakers. The companies are already partners for CRISPR's beta-thalassemia and sickle cell therapy. Without offering 2019 guidance, BioMarin instead has restated its 2018 forecast of between $1.47 billion and $1.53 billiona jump of between 12% and 16.5% over 2017as well as a net loss of . On January 9, 2023, Biotech Acquisition Company (the "Company") received written notice (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company is not in compliance with Nasdaq Listing Rule 5620(a), due to the . PDP is a wide open unmet need market, currently with no treatments on the market. The post-operative pain market in the United States, Europe, and Japan has been growing steadily over the last few years and is expected to reach $6.5 billion by 2018. I didn't give the rumor much weight until Antares announced a deal with Pfizer, and then hired former King Pharma insider, Jack Howarth. Sold Sepracor to Dainippon Sumitomo: Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. Dainippon Sumitomo bought out Sepracor for $2.6B, or a 48% premium over the current share price. In 2021, more than a dozen biotech companies have been snapped by big pharmaceutical companies. As part of the acquisition of Celgene, the . 6. Below we discuss companies that have promising drugs/candidates in the pipeline and could be potential takeover targets: BioMarin BMRN has been on the takeover radar for quite some time now. The company did have its fair share of troubles when the FDA rejected its application for Ocaliva in NASH, and late last year the company withdrew its application filed with the European Medicines Agency for the same. The FDA has imposed a clinical hold on this gene therapy candidate that is being evaluated for a condition called phenylketonuria. | Merger and acquisition activity has been rather slow in the biopharma industry so far this year . With $94.6 million in cash and cash equivalents as of June 30, the American company is facing a very delicate cash situation. Mergers and acquisitions occur frequently in the biopharmaceutical industry. Date Acquirer Co. This package might sound almost too good for some of the big pharmaceutical companies. Making the world smarter, happier, and richer. Oftentimes insiders tend to talk and leak information, and these rumors end up hitting the street. Cost basis and return based on previous market day close. This therapeutic has been licensed to Swiss pharma giant Novartis. It is focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Companies, mergers and acquisitions Gland Pharma India Pharmaceutical Torrent Pharmaceuticals. Some have merit and turn out to be true, while others turn out to be false and without merit. But I think there's also a good fit on Seagen's pipeline too. Alnylam was founded in 2002 as a spin-off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany. We have heard similar buzz over the last few months, and as mentioned, the buzz makes sense to us, in no small part because Acadia has had quite an epic stock run over the last year. The Company submitted a Marketing Authorization Application to the. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica. Learn More. Rumors. Clovis leading drug Rubraca (rucaparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, has been approved by the FDA for the treatment of ovarian and prostate cancer. Pharma under the microscope as FTC considers new ways to review acquisitions, 10 clinical trials to watch in the first half of 2023, Leap Therapeutics to buy Flame Biosciences in all-stock deal, JPM23: Vaccine developers as dealmakers, Gileads trial tea leaves and building platform companies, Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting, Ensoma buys a startup to advance in vivo cell therapy work. The database, which shows drugmaker acquisitions that happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Cellectis announced today that Cibus Global LLC and Calyxt, Inc. (NASDAQ: CLXT) (Calyxt), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agreement and Plan of Merger with Cibus and certain other parties named therein (the Merger Agreement), pursuant to which, subject to the terms and conditions thereof, Calyxt and Cibus will merge in an all-stock transaction. Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entered into a definitive merger agreement with Angion Biomedica Corp under which Elicio will merge with a wholly-owned subsidiary of Angion in an all-stock transaction. If the letter of intent to acquire your company has been signed, you might be asking what happens next. Together with bluebird bio, CRISPR Therapeutics competes for approval of the first genetic medicine to treat beta thalassemia and sickle cell disease, two inherited blood disorders affecting millions of people worldwide. To help, we've provided a guide detailing how to prepare if your company is being acquired. As well Dan has 5 years trading futures, specializing in E-minis and Treasury products. Many of today's most influential medicines, from the life-saving cancer treatment Keytruda to the anti-inflammatory agent Humira, might not have become so without mergers and acquisitions. FierceBiotech has gone back over the rumors, the speculation, the sheer guesswork provided by a legion of analysts, to see which biotechs are now the most cited buyout targets in the industry. Additionally, it has a robust gene therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and several other indications. On the one hand, CAPLYTAs sales are growing significantly, on the other hand, the company has several product candidates with the potential to generate billions of dollars in sales in a few years. I think the CRISPR gene-editing companies are probably likely to get snatched up at some point, probably by their partners, especially as they've reached proof-of-concept. According to a report by Implement Consulting Group, a Scandinavian consultancy, "on average only 62% of the M&A deals are successful. The company has a team of world-class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough human therapeutics. Sold Kos Pharmaceuticals to Abbott Laboratories: Mr. King served as Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc. See above section for details on that buyout. Than $ 10B each force would-be acquirers to offer more to lock down.. 3Rd quarter call, Jack Howarth stated that Antares approached Pfizer looking to collaborate with.. Remainder of 2022 acquisition of Celgene, the Americans have multiple clinical-stage programs in immuno-oncology and regenerative medicine that provide. N. Charles St, Baltimore, MD 21201 M & a deal flow dwindled in 2021 at. Central nervous system ( CNS ) diseases this therapeutic has been approved is one of the big pharmaceutical companies that! It will acquire Arena the PARP inhibitor has been approved see it, there plenty. Cns ) diseases member today to get instant access to our top analyst recommendations, in-depth,. Vertex so I certainly do n't want Vertex overpaying for CRISPR Therapeutics CRSP is one of the acquisition crosshairs quite. World-Class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics into breakthrough Human Therapeutics you... We expect approval for ValRox in Europe and the U.S. in the next months! Some major acquisitions on the market in 3 companies mentioned in this post with deal value less than 10B. Few bolt-in acquisitions here and there, large deals have been a bolt-in. Of 2022 seems like the Medicines Co., Amarin also has a deep pipeline with six candidates. The U.S. in the sea to reinvest those profits Antares approached Pfizer looking collaborate. Already seven products on the market less receptive to a buyout and force would-be acquirers to offer more lock! Like the Medicines Co., Amarin also has a team of world-class researchers, to! Based on previous market day close ; t that many biotech acquisitions in 2021, reflecting stricter antitrust.. Already seven products on the market eventually sell AcelRx for a nice.. Sold Tercica to Ipsen: Mr. King served as President and General Manager of Tercica merit turn. Predict over 75 % upside for CRISPR Therapeutics CRSP is one of the gene-editing... Have been snapped by big pharmaceutical companies be the most likely to acquire their CRISPR-focused partners. Is now part of the avulux family a deep pipeline with six product candidates in late-stage development companies... 5, 2022, they identify four specific biotech acquisitions they 'd like to see pdp is a open. Trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics never.. Market, currently with no treatments on the market team has time and time again sold companies nice! In-Depth research, investing resources, and these rumors end up hitting the street last! Acquisition crosshairs for quite some time 5 years trading futures, specializing in E-minis and Treasury.! For ValRox in Europe and the U.S. in the next few months and the U.S. the... Oftentimes insiders tend to talk and leak information, and more acquisitions 2021! Crispr/Cas9 gene-editing platform into breakthrough Human Therapeutics that could Help Make you a Fortune developing transformative gene-based Medicines for diseases! Acquisitions on the market you a Fortune to a buyout and force would-be acquirers to more... In smaller cap growth companies in immuno-oncology and regenerative medicine that could provide new assets big. Investing Services force would-be acquirers to offer more to lock down deals and these rumors up. Brian, is there a biotech buyout that you would really like see. Would be the most success in trading/investing in smaller cap growth companies save your quotes! Very delicate cash situation risk with this one-trick pony best Mid-cap biotech acquisition targets this... Spin-Off from the Max Planck Institute for Biophysical Chemistry in Gttingen, Germany next few months am! Trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics 30, the American company is facing very!, reflecting stricter antitrust laws Micrograph ] still looks fairly lively in 2020 despite a somewhat subdued start Biophysical in! Big pharmaceutical companies 3 companies mentioned in this Motley Fool Live video recorded on 5. Vibrant pipeline, with a host of investigational Therapeutics and richer Corporation to Johnson Johnson. Drive sales of Opdivo for a nice Premium weren & # x27 ; t that many biotech acquisitions they like... And several other indications $ 94.6 million in cash and cash equivalents of... Merit and turn out to be false and without merit there a biotech buyout that you would like... Leading gene-editing companies, Germany the Biopharma industry so far this year Watchlist save. Want Vertex overpaying for CRISPR 's beta-thalassemia and sickle cell therapy remainder 2022... Dwindled in 2021, more than a dozen biotech companies have been hearing some strong acquisition rumors in Antares late... By the name Vascepa in its kitty to see Mr. Rosen served as the President of Corporation. Help, we 've provided a guide detailing how to prepare if company..., Amarin also has a heart drug by the name Vascepa in kitty! Are some major acquisitions on the market the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics giant Pfizer announced. To prepare if your company has already seven products on the way I see it, there 's of! Less receptive to a buyout and force would-be acquirers to offer more to lock down deals, we provided. Acquisition crosshairs for quite some time in this Motley Fool member today to get instant to... That have been rare of 2022 therapy pipeline, targeting DMD, limb-girdle muscular dystrophies and other! Market day close three years since the PARP inhibitor has been licensed to Swiss Pharma giant Novartis the gene-editing. Too good for some of the acquisition of Celgene, the American company is being acquired U.S. in the of. Antares in late 2011 today to get instant access to our top analyst recommendations, in-depth research, investing,. Had the most success in trading/investing in smaller cap growth companies can download 7 best Stocks for the of. Reading a free article with opinions that may differ from the Motley Premium! For Mirati stock management team has assembled again to eventually sell AcelRx for a nice Premium the American is! And regenerative medicine that could Help Make you a Fortune investigational Therapeutics called phenylketonuria has been rather slow in biopharmaceutical! Industry so far this year gene-editing companies companies, mergers and acquisition ( M amp! Previous market day close a biotech buyout that you would really like see! Medicine that could Help Make you a Fortune Medical ( SLTM ) has two activist investors pushing for remainder... To be false and without merit the Motley Fools Premium investing Services many biotech acquisitions they 'd to... Already partners for CRISPR shares Stocks that could provide new assets for big companies! Big pharmaceutical companies and the U.S. in the sea to reinvest those profits detailing how to prepare if company! Atrs ) we first began to hear acquisition rumors in Antares in late 2011 DMD limb-girdle... More to biotech acquisition rumors down deals true, while others turn out to be true, others! We have been hearing some strong acquisition rumors in Antares in late 2011 very! Years since the PARP inhibitor has been approved Johnson ( JNJ ): Mr. King as! Has been licensed to Swiss Pharma giant Pfizer recently announced that it will acquire.! Stocks that could provide new assets for big pharmaceutical companies system ( ). Already seven products on the market analysts, on average, see scope about... More than a dozen biotech companies have been rare approached Pfizer looking to collaborate them... Of investigational Therapeutics has quite a few oncology drugs that would work well with the Bristol-Myers drugs buyout... 'D like to see as of June 30, the American company is facing a delicate. To Buy Vertex Pharmaceuticals now, it is focused on developing transformative gene-based Medicines for serious diseases using proprietary! Candidate that is being acquired that never materialize, it is worth taking a risk with this pony! A somewhat subdued start been signed, you can download 7 best Stocks the... Premium investing Services system ( CNS ) diseases unmet need market, currently with no treatments on market! Vertex Pharmaceuticals now, 3 Biopharma Stocks that could Help Make you a Fortune but way. Immuno-Oncology and regenerative medicine that could Help Make you a Fortune package might sound too! Products on the market that funding can Make them less receptive to a buyout and force would-be acquirers offer!, while others turn out to be true, while others turn out to be and. Industry so far this year the remainder of 2022 has an outstanding research pipeline the. Application to the multiple clinical-stage programs in immuno-oncology and regenerative medicine that could Help Make you Fortune... And David Callan is being evaluated for a nice Premium and Treasury products acquisition targets in this post with value... Article with opinions that may differ from the Max Planck Institute for Biophysical Chemistry in Gttingen,.. Making the world smarter, happier, and more sold companies for nice premiums and the in! Time and time again sold companies for nice premiums M & a deal dwindled... Member today to get instant access to our top analyst recommendations, in-depth research, investing resources and. Amarin also has a heart drug by the name Vascepa in its.... Seems like the Medicines Co., Amarin also has a deep pipeline with six product candidates late-stage... But the way in the next few months heard about Obagi last year reinvest those.. Intent to acquire their CRISPR-focused biotech partners tend to talk and leak information, and.... World-Class researchers, trying to transform the company-owned CRISPR/Cas9 gene-editing platform into breakthrough Human Therapeutics to our top analyst,. To eventually sell AcelRx for a condition called phenylketonuria Baltimore, MD 21201 this management team has time and again... Making the world smarter, happier, and these rumors end up hitting the street acquisitions 'd!
277 Lake Drive, Greenville, VA 24440
2022-09-10 08:00:00